Shares of Swiss drug maker Novartis AG fell Friday after an HSBC analyst downgraded the stock on concerns that generic competition will stunt Novartis' profit and revenue growth. HSBC analyst Kevin Scotcher lowered his rating to "Underweight" from "Neutral," predicting slower profit and revenue growth for Novartis over the next five years after the patents on key drugs expire. He predicted sales growth of less than 1 percent per year from 2009 through 2013.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments